GB002 (seralutinib)
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Apr 5, 2021 → Dec 1, 2027
NCT ID
NCT04816604About GB002 (seralutinib)
GB002 (seralutinib) is a phase 2 stage product being developed by Gossamer Bio for Pulmonary Arterial Hypertension. The current trial status is active. This product is registered under clinical trial identifier NCT04816604. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04816604 | Phase 2 | Active |
Competing Products
20 competing products in Pulmonary Arterial Hypertension